Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2016 - 2023)

Protalix BioTherapeutics (PLX) has 11 years of Amortization of Deferred Charges data on record, last reported at $59000.0 in Q4 2023.

  • For Q4 2023, Amortization of Deferred Charges fell 22.37% year-over-year to $59000.0; the TTM value through Dec 2023 reached $267000.0, down 11.0%, while the annual FY2023 figure was $267000.0, 11.0% down from the prior year.
  • Amortization of Deferred Charges reached $59000.0 in Q4 2023 per PLX's latest filing, down from $60000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $983000.0 in Q2 2021 and bottomed at $59000.0 in Q4 2023.
  • Average Amortization of Deferred Charges over 5 years is $485050.0, with a median of $672500.0 recorded in 2019.
  • Peak YoY movement for Amortization of Deferred Charges: increased 16.48% in 2020, then crashed 92.78% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $794000.0 in 2019, then rose by 16.12% to $922000.0 in 2020, then crashed by 88.72% to $104000.0 in 2021, then decreased by 26.92% to $76000.0 in 2022, then decreased by 22.37% to $59000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $59000.0 in Q4 2023, $60000.0 in Q3 2023, and $68000.0 in Q2 2023.